| Nr. | Year OPEN | Title | users say> | rate good | rate bad | no link | Citation |
ERKBRAFThyroid gland (Neoplasia)Haut (Neoplasia Melanoma)Thyroid gland (Neoplasm Papillary thyroid carcinoma)| 1 | 2009 | Tumour cell survival signalling by the ERK1/2 pathway. | 
| + | - | nl | Cell Death Differ 16(3):368-77 (2009) |
| 2 | 2010 | Selectively targeting mutant BRAF in thyroid cancer. | 
| + | - | nl | J Clin Endocrinol Metab 95(1):60-1 (2010) Ball DW |
| 3 | 2010 | BRAF, a target in melanoma: implications for solid tumor drug development. | 
| + | - | nl | Cancer 116(21):4902-13 (2010) |
| 4 | 2007 | Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. | 
| + | - | nl | Cancer 110(1):38-46 (2007) |
| 5 | 2007 | Targeting BRAF in thyroid cancer. | 
| + | - | nl | Br J Cancer 96(1):16-20 (2007) |
| 6 | 2009 | Integrating BRAF/MEK inhibitors into combination therapy for melanoma. | 
| + | - | nl | Br J Cancer 100(3):431-5 (2009) |
| 7 | 2007 | Clinical prognosis in BRAF-mutated PTC. | 
| + | - | nl | Arq Bras Endocrinol Metabol 51(5):736-47 (2007) |